Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, the Department of Physiology and Biomedical Engineering, the Division of Endocrinology, Department of Medicine, the Department of Surgery, and the Women's Health Research Center, Mayo Clinic, and Mayo Clinic Alix School of Medicine, Rochester, Minnesota.
Corresponding author: Elizabeth A. Stewart, MD, Division of Reproductive Endocrinology and Infertility, Mayo Clinic, Rochester, MN; email: [email protected].
Financial Disclosure Elizabeth A. Stewart reports money was paid to her institution from AHRQ/PCORI for grant P50 HS023418 and from Eunice Kennedy Shiver Institute of Child Health and Human Development, National Institutes of Health CC, for grant R01HD105714 regarding adenomyosis CC. She received payment from Bayer. She has served as consultant for AbbVie, ObsEva, and Myovant related to uterine fibroids and oral GnRH antagonists, but those companies did not support this project. She holds a patent for Methods and Compounds for Treatment of Abnormal Uterine Bleeding (US 6440445), which has no commercial activity. She has received royalties from UpToDate and payments for the development of educational content from the Med Learning Group, PER, Massachusetts Medical Society, and Peer View. She also serves as an unpaid advisor to the Fibroid Foundation. Michael F. Neblett II did not report any potential conflicts of interest. Elizabeth A. Stewart also reported that Linzagolix is discussed in this article as the third oral GnRH antagonist in development for the treatment of uterine leiomyomas, since it is approved for use in the EU despite being labeled as investigational in the United States.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at https://links.lww.com/AOG/D99.
